Menaquinone-7补充两年与冠状动脉钙化:一项随机临床试验
本研究为随机安慰剂对照试验,纳入180例有症状且CAC评分50-400 AU的冠心病患者,评估每日360 μg MK-7补充2年对CAC进展的影响。
要点
- MK-7 360 μg/日补充2年可减缓有症状冠心病患者CAC评分进展。
- 未观察到显著不良反应,但斑块稳定性的临床意义待明确。
核心结论
- 每日补充360 μg MK-7持续2年可能减缓有症状冠心病患者非钙化斑块的钙化进展。
- 该发现对斑块稳定性的临床意义尚待确定。
研究设计与样本
- 随机、安慰剂对照临床试验(VitaK-CAC研究),在荷兰1家大学医院和1家社区医院进行。
- 纳入180例有症状且CAC评分50-400 Agatston单位的患者,随机分为MK-7组(90例)和安慰剂组(90例),随访2年。
- 主要结局为1年和2年时CT测量的CAC评分和钙质量变化,次要结局包括新发钙化。
主要发现
- MK-7组血浆MK-7水平从基线中位数0.50 μg/L升至6.56 μg/L(P < .001)。
- 安慰剂组CAC评分中位数从145 AU增至1年173 AU、2年214 AU;MK-7组从135 AU增至1年150 AU、2年184 AU,组间差异显著(P = .02),校正协变量后仍显著。
- 钙质量结果与CAC评分相似。
- CAC评分增加与非钙化斑块部分钙化数量相关(R2 = 0.17;P = .04)。
- 未观察到显著不良反应。
临床怎么用
- 对于有症状的冠心病患者,可考虑每日补充360 μg MK-7以减缓冠状动脉钙化进展。
- 需结合个体情况评估,并告知患者斑块稳定性的临床获益尚未明确。
局限性
- 研究仅纳入CAC评分50-400 AU的有症状患者,结果不能外推至其他人群。
- 随访2年,长期获益与风险未知。
- 斑块稳定性的临床意义尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Vitamin K supplementation can reduce progression of vascular calcification in patients with diabetes or end-stage kidney disease. Presently, it is unknown whether vitamin K is also beneficial in patients with symptomatic atherosclerotic coronary artery disease (CAD). OBJECTIVE: To evaluate whether supplementation with the vitamin K homologue menaquinone-7 (MK-7) for a period of 2 years attenuates the progression of coronary artery calcification (CAC) compared with placebo. DESIGN, SETTING, AND PARTICIPANTS: This randomized placebo-controlled clinical trial including symptomatic patients with CAC score between 50 and 400 Agatston units (AU) with 2 years of follow-up (VitaK-CAC study). The study was conducted at 1 university hospital and 1 community-dwelling hospital in the Netherlands. Data were collected from January 2012 through October 2022 with a few interruptions; analyses were performed from January 2023 to April 2024. INTERVENTION: Supplementation with either the vitamin K homologue menaquinone-7 (MK-7) in a daily dose of 360 µg or identical placebo. MAIN OUTCOMES AND MEASURES: The primary outcome of the study was the evolution of the CAC score and calcium mass at 1 and 2 years of follow-up, as measured with computed tomography (CT) scanning. Additionally, CT angiography was performed. The incidence of new calcifications was a secondary outcome measure. Data were analyzed using a generalized estimation equations model, adjusted for covariates. RESULTS: Altogether, 180 patients could be randomized (90 patients per group), with 85 patients receiving MK-7 (median [IQR] age, 59 [54-65] years; 36 [42%] female) and 82 receiving placebo (median [IQR] age, 61 [54-65] years; 34 [42%] female). Baseline characteristics were comparable for the 2 groups. Plasma levels of MK-7 rose significantly in the active treatment group (median [IQR], 0.50 [0.32-0.77] µg/L to 6.56 [2.04-10.35] µg/L; P < .001). In the placebo group, CAC scores increased from a median (IQR) of 145 (99-217) AU to 173 (119-297) AU after the first year and to 214 (148-344) AU after the second. In the active treatment group, these values were 135 (89-226), 150 (110-254) and 184 (122-298) AU, respectively. The difference between the groups was significant (P = .02), even after adjustment for covariates. A similar result was seen for calcium mass. The increase in CAC score correlated with the number of noncalcified plaques that became partially calcified during the study (R2 = 0.17; P = .04). No significant adverse effects were observed. CONCLUSIONS AND RELEVANCE: The findings of this study suggest that supplementation with MK-7 for 2 years may slow calcification in noncalcified plaques of patients with symptomatic CAD. The clinical significance of this finding in terms of plaque stability remains to be determined. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01002157.
引用
- Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42268593. doi:10.1001/jamacardio.2026.1279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。